Implementing Procedures (7 CFR part 372).

Done in Washington, DC, this 20th day of November 2013.

Kevin Shea,

Administrator, Animal and Plant Health Inspection Service.

[FR Doc. 2013–28322 Filed 11–25–13; 8:45 am]

BILLING CODE 3410–34–P

DEPARTMENT OF AGRICULTURE

Forest Service

Ashley Resource Advisory Committee

AGENCY: Forest Service, USDA.

ACTION: Notice of meeting cancellation.

SUMMARY: The Ashley Resource Advisory Committee (RAC) meeting scheduled on the date below is cancelled. The meeting was scheduled to meet in Vernal, Utah. The RAC is authorized under the Secure Rural Schools and Community Self-Determination Act (the Act) (Pub. L. 110–343) and operates in compliance with the Federal Advisory Committee Act (FACA) (Pub. L. 92–463).

DATES: The cancelled meeting was scheduled for 6:00 p.m. on February 28, 2013.

ADDRESSES: The cancelled meeting was to be held at the Ashley National Forest Supervisor's Office, Conference Room, 355 North Vernal Avenue, Vernal, Utah. Written comments concerning this cancellation may be submitted as described under **FOR FURTHER INFORMATION CONTACT.**

All comments, including names and addresses when provided, are placed in the record and are available for public inspection and copying. The public may inspect comments received at the Ashley National Forest Supervisor's Office. Please call ahead to facilitate entry into the building to view comments.

FOR FURTHER INFORMATION CONTACT: Louis Haynes, RAC Coordinator, by phone at 435–781–5105 or email at: *lhaynes@fs.fed.us.*

Individuals who use telecommunication devices for the deaf (TDD) may call the Federal Information Relay Service (FIRS) at 1–800–877–8339 between 8:00 a.m. and 8:00 p.m., Eastern Standard Time, Monday through Friday.

Dated: November 5, 2013.

John R. Erickson,

Forest Supervisor.

[FR Doc. 2013–28189 Filed 11–25–13; 8:45 am]

BILLING CODE 3410–11–M

DEPARTMENT OF COMMERCE

Economic Development Administration

Notice of Petitions by Firms for Determination of Eligibility To Apply for Trade Adjustment Assistance

AGENCY: Economic Development Administration, Department of Commerce.

ACTION: Notice and opportunity for public comment.

Pursuant to Section 251 of the Trade Act 1974, as amended (19 U.S.C. 2341 et seq.), the Economic Development Administration (EDA) has received petitions for certification of eligibility to apply for Trade Adjustment Assistance from the firms listed below. Accordingly, EDA has initiated investigations to determine whether increased imports into the United States of articles like or directly competitive with those produced by each of these firms contributed importantly to the total or partial separation of the firm's workers, or threat thereof, and to a decrease in sales or production of each petitioning firm.

LIST OF PETITIONS RECEIVED BY EDA FOR CERTIFICATION ELIGIBILITY TO APPLY FOR TRADE ADJUSTMENT ASSISTANCE

[11/07/2013 through 11/20/2013]

Firm name	Firm address	Date accepted for investigation	Product(s)
DryCase, LLC	349 Military Cutoff Road, Wilmington, NC 28405.	11/08/2013	The firm manufactures waterproof bags for electronic devices.
Benchmark Clothing Company, Inc. (dba—Benchmark Clothing and Benchmark FR).	1521 East McFadden Suite F, Santa Ana, CA 92705.	11/08/2013	The firm manufacturers flame resistant garments.

Any party having a substantial interest in these proceedings may request a public hearing on the matter. A written request for a hearing must be submitted to the Trade Adjustment Assistance for Firms Division, Room 71030, Economic Development Administration, U.S. Department of Commerce, Washington, DC 20230, no later than ten (10) calendar days following publication of this notice.

Please follow the requirements set forth in EDA's regulations at 13 CFR 315.9 for procedures to request a public hearing. The Catalog of Federal Domestic Assistance official number and title for the program under which these petitions are submitted is 11.313, Trade Adjustment Assistance for Firms.

Dated: November 20, 2013.

Michael DeVillo,

Eligibility Examiner.

[FR Doc. 2013–28302 Filed 11–25–13; 8:45 am]

BILLING CODE 3510–WH–P

DEPARTMENT OF COMMERCE

Foreign Trade Zones Board

[B–98–2013]

Foreign-Trade Zone (FTZ) 93—Raleigh/Durham, North Carolina; Notification of Proposed Production Activity; GlaxoSmithKline, PLC (Pharmaceutical Products); Zebulon, North Carolina

The Triangle J Council of Governments, grantee of FTZ 93, submitted a notification of proposed production activity to the FTZ Board on behalf of GlaxoSmithKline, PLC (GlaxoSmithKline), located in Zebulon, North Carolina. The notification conforming to the requirements of the regulations of the FTZ Board (15 CFR 400.22) was received on November 18, 2013.

The GlaxoSmithKline facility is located within Site 6 of FTZ 93. The facility is used for the production and packaging of pharmaceutical products. Pursuant to 15 CFR 400.14(b), FTZ activity would be limited to the specific foreign-status materials and components and specific finished products listed in the submitted notification (as described below) and subsequently authorized by the FTZ Board.

Production under FTZ procedures could exempt GlaxoSmithKline from

customs duty payments on the foreign status components used in export production. On its domestic sales, GlaxoSmithKline would be able to choose the duty rates during customs entry procedures that apply to inhalers, tablets, and capsules which treat a variety of medical conditions (duty rates range from free to 6.4%) for the foreign status inputs noted below. Customs duties also could possibly be deferred or reduced on foreign status production equipment.

The finished products include devices such as respiratory placebo inhalers, Relenza anti-viral inhalers, Seretide/Advair, Serevent and Flovent diskus respiratory inhalers, Advair and Ventolin HFA respiratory inhalers, and the following tablets and capules—Lovaza antihyperlipidemic, Paxil depression, Avandamet metabolic, Avandary metabolic, Avandia metabolic, Lamictal central nervous system (CNS), Potiga CNS, Amerge CNS, Horizant CNS, Imitrex CNS, Lamictal ODT CNS, Requip/Requip XL CNS, Treximet CNS, Telzir anti-viral, Valtrex anti-viral, Zovirax anti-viral, Wellbutrin/Buproprion depression, Zantac gastrointestinal (GI), Zofran GI, Votrient urology, Coreg CR cardiovascular, Rythmol cardiovascular, Innopran XL hypertension, Jalyn urology, Avodart urology, Lanoxin cardiovascular, Malarone anti-malarial, Promacta immune thrombocytopenia (ITP), and Tykerb oncology.

The components and materials sourced from abroad include corn starch, carnuba wax, lactose monohydrate, fluticasone/salmeterol placebo diskus (a type of inhaler), respiratory placebo inhaler, silica colloidal anhydrous, precipitated calcium carbonate, pharmaceutical talc, zephex 134a propellant, mannitol, magnesium stearate, stearic acid, potassium sorbate, propafenon hcl, bupropion hydrochloride, melphalan, albuterol sufate, salbuterol sulfate, salmeterol, vilanterol trifenatate, umeclidinium api, paracetamol, ezogabine (retigabine), paracetamol, metformin hydrochloride, ranitidine hydrochloride, zanamivir, ondansetron hydrochloride, abacavir sulfate, valacyclovir hydrochloride, lamotrigine, rosiglitazone maleate, paroxetine hydrochloride, lamivudine, zidovudine, pazopanib, fluticasone propionate, fluticasone furoate, dutasteride, Lovaza capsules, breo ellipta inhalers, avodart capsules, flovent diskus, Paxil tablets, lexiva oral suspension, sumatriptan succinate/naproxen (Treximet), abacavir/lamivudine tablets (epzicom) tablets, atovaquone and proguanil hcl tablets, combivir tablets, dolutegravir tablets, epivir tablets, epzicom tablets, malarone tablets, ziagen tablets, Zantac tablets, mekinist tablets, trametinib tablets, pazopanib tablets, tafinlar capsules, votrient tablets, coreg cr capsules, flolan for injection, propafenon sr, Rythmol (proafenon) sr, Amerge tablets, imigran injection, imitrex bulk pack, sumatriptan succinate 85mg/naproxen, lamictal, parnate tablets, ondansetron odt bulk, requip tablets, soriatane (acitretin) capsules, Zofran, Ventolin actuator dose counter, Advair diskus, Advair diskus inhalation powder, fluticasone/salmeterol aerosol inhalers, Ventolin samples, Seretide, argatroban, arixtra, Avandamet tablets, Avandia tablets, dutasteride-tamsulosin hcl fdc capsules, eltrombopag, flolan sterile diluent, Jalyn fixed dose combination capsules, panadol tablets, opadry (an excipient), starch pregel, Avandamet placebo tablets, placebo diskus, nasal spray demo pack, respiratory placebo, triacetin, crospovidone, povidone, spectracel, alginic acid ep, 20 micron aluminum powder, empty aerosol cans, pressure can spray valves, diskus subassemblies, multi-dose powder inhalers, novel dry powder inhalers, multi-dose powder inhaler subassembly and placebo, multi-dose powder inhaler diskus devices, actuators—and their dose counters and assemblies (duty rates range from free to 6.5%).

Public comment is invited from interested parties. Submissions shall be addressed to the FTZ Board's Executive Secretary at the address below. The closing period for their receipt is January 6, 2014.

A copy of the notification will be available for public inspection at the Office of the Executive Secretary, Foreign-Trade Zones Board, Room 21013, U.S. Department of Commerce, 1401 Constitution Avenue NW., Washington, DC 20230–0002, and in the ''Reading Room'' section of the FTZ Board's Web site, which is accessible via *www.trade.gov/ftz.*

For further information, contact *Diane.Finver@trade.gov* or (202) 482–1367.

Dated: November 19, 2013.

Andrew McGilvray,

Executive Secretary.

[FR Doc. 2013–28353 Filed 11–25–13; 8:45 am]

BILLING CODE 3510–DS–P

DEPARTMENT OF COMMERCE

Foreign-Trade Zones Board

[B–99–2013]

Notification of Proposed Production Activity, Hitachi Automotive Systems Americas, Inc., Subzone 29F, (Automotive Electric-Hybrid Drive System Components), Harrodsburg, Kentucky

The Louisville and Jefferson County Riverport Authority, grantee of FTZ 29, submitted a notification of proposed production activity to the FTZ Board on behalf of Hitachi Automotive Systems Americas, Inc. (HIAMS–HK), operator of Subzone 29F, at its facilities located in Harrodsburg, Kentucky. The notification conforming to the requirements of the regulations of the FTZ Board (15 CFR 400.22) was received on November 12, 2013.

HIAMS–HK already has authority to produce various automotive components, including mass air sensors, throttle bodies and chambers, starter motors, motor/generator units, alternators, distributors, other static converters, inverter modules, rotors/stators, batteries, ignition coils, sensors and modules, fuel injectors, emissions control equipment, valves, pumps, and electronic control units for engines and transmissions within Subzone 29F. The current request would add finished products (lithium-ion hybrid battery pack assemblies, electrical power steering modules, and electronic torque, traction and transmission control modules) and certain foreign components to the scope of authority. Pursuant to 15 CFR 400.14(b), FTZ activity would be limited to the specific foreign-status components and specific finished products described in the submitted notification (as described below) and subsequently authorized by the FTZ Board.

Production under FTZ procedures could exempt HIAMS–HK from customs duty payments on the foreign status components used in export production. On its domestic sales, HIAMS–HK would be able to choose the duty rates during customs entry procedures that apply to lithium-ion hybrid battery pack assemblies, rotors A&B, stators A&B, electrical power steering modules, and electronic torque, traction and transmission control modules (free–3.4%) for the foreign status inputs noted below and in the existing scope of authority. Customs duties also could possibly be deferred or reduced on foreign status production equipment.

The components and materials sourced from abroad include: Plastic